OZEM ETF Holdings

ETF Components for OZEM - Roundhill GLP-1 & Weight Loss ETF

Below is a list of stocks held by this ETF. We only list holdings in the same market. If this is a global ETF, there may be additional components other than those listed here.

Holdings

Symbol	Grade	Price % Change	Allocation
NVO	F	-0.01	17.47
LLY	F	-1.30	15.52
AZN	F	0.38	4.28
VKTX	A	0.47	3.69
ALT	D	0.00	3.69
AMGN	C	-0.29	3.25
PFE	D	-0.74	3.15
SRRK	B	-0.07	2.62
REGN	F	0.64	2.61
TERN	D	1.17	2.14
TAK	C	0.14	1.96
RYTM	D	2.68	1.70
CORT	B	-2.76	1.43
OPK	C	0.00	1.35

Represented by ETF Holdings

Keywords: Biopharmaceutical Obesity Pharmaceutical Products Cancer Inflammation Biotechnology Diabetes Medicine Neuroscience S&P 500 Alzheimer's Disease Anemia Asthma Cholesterol Depressive Disorder Hormones Hypertension Life Sciences Major Depressive Disorder Medication

Industries: Biotechnology Drug Manufacturers - Major Drug Manufacturers - Specialty & Generic

Recent News for Roundhill GLP-1 & Weight Loss ETF & its Holdings

Date	Stock	Title
Nov 1	NVO	Election Day, Fed decision, earnings: What to Watch Next Week
Nov 1	LLY	Lilly to Present Results from Phase 3 EMBER-3 Study of Imlunestrant, an Oral SERD, and Additional Results from Its Breast Cancer Portfolio at the San Antonio Breast Cancer Symposium
Nov 1	LLY	Market Volatility Soars Ahead Of Elections, Tech Earnings Mixed, Strikes And Hurricanes Knock Employment Down: This Week In The Markets
Nov 1	VKTX	Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH
Nov 1	LLY	Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH
Nov 1	LLY	Pharma Stock Roundup: MRK, PFE, ABBV, NVS, LLY's Q3 Earnings in Focus
Nov 1	PFE	Pharma Stock Roundup: MRK, PFE, ABBV, NVS, LLY's Q3 Earnings in Focus
Nov 1	NVO	Why iShares’ Europe ETF (IEUR) May Be Attractive for U.S. Investors
Nov 1	NVO	Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH
Nov 1	LLY	Stocks to watch next week: Berkshire Hathaway, Super Micro, Novo Nordisk, Vistry and M&S
Nov 1	CORT	Earnings Estimates Moving Higher for Corcept (CORT): Time to Buy?
Nov 1	LLY	Hims & Hers Health Faces Pressure Ahead of Earnings Amid Eli Lilly's GLP-1 News
Nov 1	NVO	Novo Nordisk's Semaglutide Trial Shows 'Superior Improvement' in Liver Fibrosis, MASH
Nov 1	PFE	3 Reasons Relying on Social Security Alone Could be a Risk. And 3 Stocks to Invest in Today.
Nov 1	NVO	Novo Nordisk Says Wegovy Improved Patients’ Liver Disease
Nov 1	PFE	Cancer-Focused ESSA Pharma Ends Prostate Cancer Trial Due to Insufficient Efficacy From Combination Therapy
Nov 1	LLY	Popular Weight Loss Drug Wegovy Shows Encouraging Results in Liver Fibrosis Trial
Nov 1	NVO	Popular Weight Loss Drug Wegovy Shows Encouraging Results in Liver Fibrosis Trial
Nov 1	REGN	What Makes Regeneron Pharmaceuticals (REGN) an Attractive Investment Opportunity?
Nov 1	NVO	Novo Nordisk posts Phase 3 win for obesity drug in MASH

OZEM targets the global weight management industry. The fund invests in companies involved in the development of GLP-1 and other weight loss drugs. GLP-1 agonists seek to aid in weight management by lowering blood sugar levels, reducing appetite, and promoting fullness. The portfolio consists of firms with GLP-1 and weight loss drugs that have been approved by or are currently undergoing Phase I, Phase II, and/or Phase III clinical trials of the US Food & Drug Administration (FDA), or any applicable food and drug regulator for non-US companies. The portfolio is constructed using a proprietary methodology, which selects companies with high levels of thematic relevance based on research of each companys public filings and disclosures. In addition, eligible securities must meet minimum market-cap and liquidity requirements. The actively managed fund, although rebalances portfolio weighting on at least a quarterly basis, may have a heavy concentration on a few names.
Weight Management Peptide Therapeutics

Back to the Main OZEM Page...